BlossomHill Therapeutics, Inc. Common Stock Total Assets
BlossomHill Therapeutics, Inc. Common Stock total assets. Based on the latest financial reports, BlossomHill Therapeutics, Inc. Common Stock (BLSM) holds total assets worth $143.41 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is BlossomHill Therapeutics, Inc. Common St worth for the company's overall valuation and market capitalisation.
Total Assets of BlossomHill Therapeutics, Inc. Common Stock (2024–2025)
Total assets of BlossomHill Therapeutics, Inc. Common Stock from 2024 to 2025. This chart illustrates how BlossomHill Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See BLSM stock price and chart for real-time trading data and today's change.
BlossomHill Therapeutics, Inc. Common Stock - Asset Composition Analysis
BlossomHill Therapeutics, Inc. Common Stock Total Assets Breakdown (December 2025)
BlossomHill Therapeutics, Inc. Common Stock total assets breakdown as of December 2025. BlossomHill Therapeutics, Inc. Common Stock's total assets of $143.41 Million consist of 85.2% current assets and 14.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 83.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $89.00K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how BlossomHill Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BlossomHill Therapeutics, Inc. Common St (BLSM) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BlossomHill Therapeutics, Inc. Common Stock's current assets represent 85.2% of total assets in 2025, a decrease from 97.6% in 2024.
- Cash Position: Cash and equivalents constituted 83.9% of total assets in 2025, down from 93.8% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is intangible assets at 0.1% of total assets.
BlossomHill Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of BlossomHill Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
BlossomHill Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.40 | - | - |
| Quick Ratio | 7.40 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | $103.55 Million | - | - |
BlossomHill Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between BlossomHill Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 2.21 |
| Asset Growth Rate (YoY) | 52.6% |
| Total Assets | $162.97 Million |
| Market Capitalization | $360.02 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values BlossomHill Therapeutics, Inc. Common Stock's assets at a significant premium (2.21x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: BlossomHill Therapeutics, Inc. Common Stock's assets grew by 52.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BlossomHill Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual total assets of BlossomHill Therapeutics, Inc. Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $162.97 Million | +52.63% |
| 2024-12-31 | $106.78 Million | -- |
About BlossomHill Therapeutics, Inc. Common Stock
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients w… Read more